We developed a hybrid method for predicting plasma concentration-time curves in humans by integrating species differences in in vitro intrinsic clearance (CL int ) into the Dedrick approach based on the allometry concept. With prediction of clearance (CL) by allometric scaling, taking in vitro CL int into consideration improved the accuracy and reduced the average fold error from 2.72 to 1.99. With the hybrid approach of applying the same concept to the Dedrick approach, the predictability of plasma concentration profiles was compared with the results of the conventional Dedrick approach and the physiologically based pharmacokinetic model using 15 compounds with widely ranging physicochemical and pharmacokinetic profiles. The hybrid approach showed the highest predictability among the examined methods. For CL and the apparent volume of distribution at the steady state (V ss ), the relationship between the exponent of allometric equation and fold error was also evaluated with the hybrid approach. The relationship appeared to be a horseshoe curve. Six compounds with exponents ranging from 0.7 to 1.1 for both CL and V ss [antipyrine, caffeine, epiroprim, propafenone, theophylline, and verapamil] displayed higher predictability. Three compounds with an exponent ranging from 0.7 to 1.1 for CL showed better predictability for CL, and the other four compounds appeared to display similar relationship between the exponent and predictability for V ss . These findings indicated that the exponent becomes a preliminary index to speculate on predictability. Combination of the hybrid approach and exponent allows us to prospectively draw human plasma concentration-time curves, with the implication of possible prediction accuracy prior to clinical studies.
Introduction
For pharmaceutical companies, the prediction of human pharmacokinetics has increasingly become a critical issue, not only to narrow down development candidates to a development compound with a desirable pharmacokinetic profile in humans, but also to design firstin-human studies of such a compound including appropriate starting dose and dose escalation. The nonclinical pharmacokinetics department is required to conduct reliable prediction of pharmacokinetic parameters such as total body clearance (CL) and apparent volume of distribution at the steady state (V ss ) in humans and also to describe plasma concentration-time profiles in humans simulated by the use of those parameters.
A widely used methodology for predicting the plasma concentrationtime profiles is a physiologically based pharmacokinetic (PBPK) model incorporating in vitro intrinsic clearance (CL int ) (Poulin and Theil, 2002; Peters, 2008; Jamei et al., 2009; Jones et al., 2011) . Approximately 50% of all drugs undergo hepatic metabolism by cytochrome P450 (P450) enzymes (Williams et al., 2004) , and some authors demonstrated the usefulness of the PBPK model in the prediction of human pharmacokinetics by including this strategy in drug development (Jones et al., 2006; De Buck et al., 2007) . Over the last decade, the advent of in vitro transporter expression systems revealed that liver uptake and biliary and/or renal excretion involving transporters are determinant factors in the pharmacokinetics of some compounds (Shitara et al., 2006; Poirier et al., 2009; Watanabe et al., 2010; Jones et al., 2012) . Retrospective prediction based on the PBPK model including liver uptake mechanisms successfully described plasma concentration-time curves of a limited number of the compounds (Watanabe et al., 2009) . However, it is difficult to elucidate the mechanisms governing the pharmacokinetics of development candidates in in vitro studies using chemical inhibitors of P450 enzymes and transporters or their in vitro expression systems alongside the relevant in vivo studies within a restricted timeframe due to the laborintensive and time-consuming processes.
Another technique for predicting human plasma concentration profiles is the Dedrick approach, which is based on the allometric scaling theory (Dedrick et al., 1970; Lave et al., 1995; Van den Bergh et al., 2011) . The Dedrick approach can describe the plasma concentration-time curves in humans from the relevant profiles in animal species by transforming the chronological time into the biologic time based on the allometric theory for CL and V ss , which are scaled across the species as a power function of body weight. In contrast to the PBPK models, the Dedrick approach can be adapted to compounds with various mechanisms of elimination and distribution. However, allometric scaling tends to produce overpredicted CLs (Tang and Mayersohn, 2006) . Especially, in case of compounds that display a large species difference in CL dependent on hepatic metabolism, allometric scaling tends to yield poor prediction accuracy (Lave et al., 1997) . This can be ascribed to the concept of allometry, namely that any difference in pharmacokinetics across species is defined by body size alone.
How to improve predictability has become a crucial question to be addressed, and much effort has been made to improve the predictability of allometric scaling (Mahmood, 2002; Mahmood, 2006; Hosea et al., 2009) . Lave et al. (1996a Lave et al. ( , 1997 proposed allometric scaling involving CLs corrected by in vitro CL int in the hepatocytes of human and animal species. Although the same concept was still applied to the Dedrick approach, the predictability of the plasma concentration profile in humans was only demonstrated by one compound (Lave et al., 1996b) . Therefore, utility of the hybrid approach based on the integration of Dedrick plot and the species difference in in vitro CL int has to be evaluated, including comparative analysis with the PBPK model, for a number of test compounds with widely diverse physicochemical properties.
In the present study, the predictability of the hybrid approach was evaluated using 15 compounds that had been characterized in vitro and in vivo, and it was compared with the predictability of the Dedrick method and the PBPK model. Exponents of the allometric scaling are also regarded as important parameters in the choice of scaling methods such as the rule of exponent (ROE) method (Mahmood, 2006) . When the exponents of CL and/or V ss were found to correlate with the prediction accuracy of the hybrid approach, it was possible that the exponent became an index for the predictability of human pharmacokinetic profiles. We evaluated the relationship between the two parameters and the impact of the exponent on the prospective analysis of predictability of the hybrid method before clinical studies.
Materials and Methods
Data Collection. For prediction of CL and V ss by allometric scaling, 92 compounds in total (21 for CL and 86 for V ss ) that were reportedly available for intravenous pharmacokinetic parameters and in vitro CL int in the liver microsomes or hepatocytes were collected from the literature. When the in vitro CL int was reported as the unit of milligrams microsomal protein or million cells of hepatocytes, the value was converted to the unit of milligrams per minute per kilograms of body weight using 45 mg microsomal protein/g of liver or 1Â10 6 cells/g of liver and corresponding liver weight for each species (Barter et al., 2007) . These in vivo and in vitro parameters are listed as the supplemental data (Supplemental Table 1 ). Among these, 15 model compounds, of which the plasma concentration data in animals and humans after intravenous administration were reported, were selected and used for the prediction of plasma concentration-time profiles in humans using the hybrid approach, the Dedrick approach, and the PBPK model ( Table 1 ). Note that profiles of the lipophilicity (clogP) and CL for 15 model compounds selected were similar to those in compounds listed in Supplemental Table 1 . For prediction using the PBPK model, additional in vitro data including the unbound fraction in the plasma (fu p ) and the blood to plasma concentration ratio (R B ) in humans were obtained from the literature, and clogP, pH-dependent measure of lipophilicity (clogD), and basic and acidic dissociation constants (pK a ) were calculated using CLOGP, version 4.82 (Daylight Chemical Information Systems, Laguna Niguel, CA) and Pallas, version 4.4.1 (CompuDrug Inc., Sedona, AZ). The compounds were divided into acidic, basic, and neutral classes based on the difference between the clogD values at pH 6.5 and 7.4 (ΔclogD) as indicated in the following equation:
The compounds with positive and negative values of ΔclogD were classified as acidic and basic, respectively. The physicochemical and pharmacokinetic characteristics of the 15 model compounds are summarized in Table 1 . Prediction of CL and V ss by Allometric Scaling. In vivo CL and V ss of each animal species were plotted against the body weight on a log-log scale, and the conventional allometric equation was used to predict CL and V ss in humans as shown in the following equations:
where BW is the body weight, a and b are the coefficients, and x and y are the exponents of the allometric equation obtained from the animals. The body weight in humans was assumed to be 70 kg.
In addition, the allometric scaling of CL was integrated with the in vitro CL int in animals and humans to correct the species difference in CL; namely, the CL in animals was corrected by in vitro CL int and was plotted against the body weight using the following equation.
The subsequent procedure for human CL prediction in the integrated method was the same as the allometric scaling described above. The allometric scaling was conducted using all of the species (2-5 animal species) listed in Supplemental Table 1 . Because two-species scaling reportedly provided reliable CL (Tang et al., 2007; Goteti et al., 2010) , the prediction based on more than two animal species would be considered acceptable.
Prediction of Plasma Concentrations: the Hybrid and Dedrick Approaches. Prediction of plasma concentration was conducted according to the method reported by Dedrick et al. (1970) and Boxenbaum and Ronfeld (1983) . In brief, assuming that CL is proportional to BW x and volume of the central compartment (V 1 ), volume of distribution during the b-phase (V b ) and V ss are all proportional to BW y (x and y are the exponent of CL and V ss , respectively, in animals), plasma concentration-time profile of twocompartmental model can be described by the body weight, compound specific coefficients (intercept in allometric equation, e.g., a and b), and exponents (x and y). On the basis of this theory, the chronologic time in humans (t human ) can be derived from the chronologic time in animals (t animal ) according to the following equation:
Plasma concentrations in humans (C human ) were calculated from those in animals (C animal ) as described below.
These C human were plotted against t human and were fitted to a biexponential pharmacokinetic equation. Human pharmacokinetic parameters (k 10 , k 12 , k 21 , and V 1 ) were obtained using Phoenix WinNonlin, version 6.3 (Pharsight, Sunnyvale, CA).
To correct the interspecies difference in hepatic metabolism, the in vitro CL int in animals and humans was incorporated in the following equation to calculate t human by the hybrid approach:
The following processes including the calculation of C human and parameter fitting were carried out in the same manner as with the Dedrick approach described above. The hybrid and Dedrick approaches were conducted using all of the species listed in the Table 1 . Prediction of Plasma Concentrations: PBPK. A typical PBPK model used to predict plasma concentrations in humans is shown in the supplemental data (Supplemental Fig. 2) . The model is composed of 11 tissue compartments, consisting of the lungs, adipose tissue, bones, brain, heart, muscles, kidneys, spleen, liver, skin, and small intestine, which are linked by venous and arterial blood pools. Perfusion rate-limited kinetics was assumed and each tissue was represented by a single well-stirred compartment, limited by the blood flow. The liver was considered only on the elimination site. The principles of mass balance equations for noneliminating tissues and eliminating tissue (the liver) are indicated by the following differential equations:
where V is the volume, Q is the blood flow, C is the concentration, and subscript T is tissue, and subscript a is artery. In vitro CL int in humans obtained from the literature was used in the model, assuming that the unbound fraction in the in vitro system (fu inc ) was equal to the unbound fraction in blood (fu B ) and both parameters were canceled out, as reported by De Buck et al. (2007) . The K p values of 11 tissues were calculated using the tissue composition-based equations described by Rodgers and coworkers (Rodgers et al., 2005; Rodgers and Rowland, 2006) . The respective equations (eqs. 10 and 11) used for strong 
where f is the fraction tissue volume (subscripts IW, EW, NL, NP refer to intracellular water, extracellular water, neutral lipids, and neutral phospholipids, respectively), [PR] T is the tissue concentrations of proteins (acidic phospholipid for strong bases, albumin for weak bases, and acid and lipoprotein for neutral drugs), and K aPR is the affinity constant of the drug for each protein.
Physiological parameters used in the PBPK model, and the tissue compositionbased equations are listed as the supplemental data (Supplemental Table 2 ). This PBPK model was constructed and solved with Phoenix WinNonlin. Assessment of Prediction Accuracy. The plasma concentrations in humans were simulated by three different methods: the Dedrick approach, the hybrid approach, and the PBPK model. The V ss , CL, and elimination half-life (t 1/2 ) with each method were estimated by noncompartmental analysis of the simulated plasma concentration-time profile using Phoenix WinNonlin. The predictability in individual drugs was evaluated based on the fold error using the following equations: 
where n represents the number of compounds evaluated. In addition, the percentage of compounds within the twofold or threefold error was derived from comparison between the predicted and observed parameters. Comparative assessment of predictability for CL, V ss , and/or t 1/2 between the examined methods was performed mainly based on afe and/or the percentage within twofold or threefold.
Results
Allometric Scaling of CL with In Vitro Cl int . The human CLs predicted using allometric scaling with or without the correction factor of in vitro CL int were compared with the observed values (Fig. 1) . The relationship between the observed and predicted CLs was remarkably improved by the introduction of the correction factor. With the conventional method without in vitro CL int , the afe was calculated to be 2.72, and 52% of the compounds examined were predicted within twofold error of the observed values ( Table 2 ). The use of in vitro CL int as the correction factor into the allometric scaling increased the predictability with an afe of 1.99, and 62% of the compounds were predictable within twofold error.
Prediction of Plasma Concentration-time Profiles by Hybrid Approach. The hybrid method based on integration of the Dedrick plot and the in vitro CL int was applied to predict plasma concentration-time curves in humans, and the obtained profiles were compared with the corresponding data derived from the conventional Dedrick approach and PBPK model. We selected 15 compounds of which reported in vitro and in vivo pharmacokinetic parameters were available, covering a wide range of physicochemical and pharmacokinetic parameters ( Table 1) . The plasma Fig. 2 . The pharmacokinetic parameters CL, V ss , and t 1/2 were estimated based on the plasma concentration-time curves predicted by the individual method, and the relationship between the observed and predicted parameters is shown in Fig. 3 . The fold-error and/or the afe are also summarized in Tables 3 and 4. The predictability of CL, V ss , and t 1/2 was the highest with the hybrid approach using a correction factor of in vitro CL int followed by the conventional Dedrick approach . the PBPK model. For predictability of CL, V ss , and t 1/2 with the hybrid approach, the afe was calculated to be 1.74, 1.54, and 2.13, and 67%, 73% and 53% of the compounds were within twofold error of the observed data, respectively. With regard to antipyrine, caffeine, diazepam, epiroprim, nicardipine, propafenone, propranolol theophylline, and dmd.aspetjournals.org verapamil, the hybrid approach yielded visual plasma concentrationtime curves that were close to the observed concentrations, relative to the PBPK model (Fig. 2) . Relationship between Exponent and Predictability. To find a preliminary index describing the prediction accuracy of compounds with the hybrid approach, the relationship between the exponent and fold error was evaluated for CL and V ss projections by allometric scaling (Fig. 4) , and the predictability in three categories based on the exponent range (all, 0.7-1.1, or ,0.7 and .1.1) are summarized in Table 5 . With the allometric scaling of CL using the correction factor, the compounds of which the exponents ranged from 0.7 to 1.1 exhibited high accuracy such as an afe of 1.53, and predictability was within twofold error for 92% of the compounds, whereas relatively low accuracy was demonstrated with the other compounds with an exponent of ,0.7 or .1.1. The predictability of V ss with allometric scaling using all the examined compounds seemed relatively low, and predictability was within twofold error of the observed values for 65% of the compounds. However, when compounds of which the exponent ranged from 0.7 to 1.1 were evaluated with the V ss prediction, the percentage of compounds with predictability within twofold error appeared to increase (Fig. 4) , and predictability was within twofold error of the observed values for 80% of the compounds (Table 5) . In contrast, low accuracy was observed with compounds with an exponent of ,0.7 or .1.1, as indicated by predictability within twofold error for 19% of the compounds.
These results demonstrated that the exponent of allometric scaling would possibly be an advance speculative indicator of the predictability of CL and V ss . Similarly, with the hybrid approach, the exponent was plotted against the fold error of CL and V ss that was obtained from the plasma concentration profiles (Fig. 5) , and the estimated afe in three categories was based on the exponent range as summarized in Table 6 . As illustrated in Fig. 5 , relatively high accuracy was found with compounds with an exponent from 0.7 to 1.1, and this trend was more prominent with the CL data. The 15 compounds were classified into four groups based on the exponent of CL and V ss (Table 7) ; that is, group 1 was characterized by the exponent ranging from 7 to 1.1 for both CL and V ss , groups 2 and 3 by the exponent range of 0.7-1.1 for CL and 0.7-1.1 for V ss , respectively, and group 4 by the exponent range of ,0.7 and .1.1 for both CL and V ss (data not shown). Interestingly, six compounds (antipyrine, caffeine, epiroprim, propafenone, theophylline, and verapamil) in group 1 provided the highest level of accuracy with an afe of 1.29 for CL, 1.40 for V ss , and 1.89 for t 1/2 . Group 2 [felodipine, propranolol, tolcapone] and group 3 [diltiazem, midazolam, nicardipine, oxazepam (Serax)] also showed better accuracy for CL and V ss , respectively. 
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Discussion
This study successfully demonstrated that the integration of species difference in in vitro CL int in the Dedrick approach improved the predictability of plasma concentration-time curves. It is also of particular note that it is clearly shown that the hybrid approach, which is based on empirical and physiological concepts, produces better predictability than the PBPK model, which is based on the metabolic clearance in the liver defined by in vitro CL int and the tissue distribution defined by plasma protein binding and physicochemical properties (clogP, clogD, and pK a ).
Animal scale-up based on the allometry concept has been widely used to predict pharmacokinetic parameters in humans (Shiran et al., 2006; Tamaki et al., 2011) , and there have been advantages and disadvantages in the predictions by this method. In general, development of PBPK model needs clarification of elimination mechanisms from the body; however, in the drug discovery phase, detailed investigation for the major elimination mechanism of an individual development candidate is practically difficult within the limited timeframe. One advantage is that allometric scaling can easily be applied to most of the compounds regardless of their elimination mechanism, which is different from the PBPK model, which needs modeling of the mechanism after it was elucidated.
Overprediction of CL has been recognized as a disadvantage and, in the worst case, will generate vertical allometry (Tang and Mayersohn, 2006) . This was also understandable by the CL data predicted in the present study showing that 80% of the compounds with predictability of over twofold error were overestimated by allometric scaling without in vitro CL int (Fig. 1) . Importantly, the application of in vitro CL int obtained from liver microsomes or hepatocytes with allometric scaling of CL improved the prediction accuracy, as evidenced by Lave et al. (1996a Lave et al. ( , 1997 . Similarly, the hybrid method developed using the Dedrick plot and in vitro CL int in the species provided high accuracy to predict the plasma concentration-time curves. Noticeably, the predictability of t 1/2 derived from their concentration profiles was higher than with the PBPK model, probably for 11 out of 15 compounds.
There has been a limited number of reports that the predictability of plasma concentration-time curves was comparatively evaluated between the two different concepts (empirical approach versus the PBPK model). Yamazaki et al. (2011) demonstrated that a PBPK model provided better prediction of the maximum plasma concentration and the area under the plasma concentration-time curves for two compounds than a traditional one-compartment model based on CL and V ss predicted by allometric scaling. Comparative analysis between the Dedrick and PBPK approaches was conducted by Jones et al. (2006) , who employed 19 compounds with a wide range of CL and V ss . The prediction accuracy was higher with the PBPK model than the Dedrick approach. However, the former study employed a simplified one-compartment model, which is regarded as a low predictability model, and the latter study did not use any correction factor such as maximum life span potential (MLP), brain weight (BrW), or in vitro metabolic data with the Dedrick approach.
As an alternative approach with the empirical method, there was the Wajima method in which plasma-concentration time curves were predicted from pharmacokinetic data in animals (Wajima et al., 2004; Fura et al., 2008; Van den Bergh et al., 2011) ; that is, the plasma concentration-time curves can be normalized by a time axis with mean residence time and a plasma concentration axis with dose/V ss . Comparative assessment using the Pharmaceutical Research and Manufacturers of America initiative concluded that the Wajima method and the PBPK model provided a similar level of accuracy on the intravenous dataset (Vuppugalla et al., 2011) . However, the Dedrick approach was not used in the comparison study. Our result is the first report demonstrating better predictability with the hybrid approach than the PBPK model, and this significance in the hybrid method would be attributable to the use of species difference in in vitro CL int . Our preliminary study also indicated that the hybrid approach was applicable to compounds that are mainly subject to biliary excretion in rats and that it had higher accuracy than the PBPK model used in this study (data not shown). It should be noted that our findings were derived from 15 compounds that showed various physicochemical properties (clogP; 20.04-5.30 ) and pharmacokinetic profiles in humans (fu p ; 0.001-1, CL; 0.50-19.23 ml/min/kg, V ss ; 124-5731 ml/kg). One of the major concerns of the physiological approach is underestimation of CL (Ito and Houston, 2005; Hallifax et al., 2010) .
In this study, this trend was also found for the relationship between the observed and predicted CL obtained with the PBPK model (Fig. 3) . Hence, several pharmacokinetic scientists have gone to much effort to improve the predictability. For example, an empirical scaling factor to extrapolate the in vitro CL int from microsomes or hepatocytes to the whole body was employed (Ito and Houston, 2005) . Naritomi et al. (2001; 2003) also developed an animal scaling factor, which was estimated by comparing in vitro and in vivo CL int in rats or dogs, and using the factor ameliorated the predictability of in vitro-in vivo extrapolation of CL. However, PBPK models are basically a rationalized approach. Hence, because the PBPK model yielded lower predictability than the hybrid method in the present study, mechanistic models to seal the gap between the observed and predicted data would necessarily be taken into consideration.
The findings in the present study imply that the hybrid approach is a highly predictable method for many compounds with widely ranging lipophilicity, which is one of the determinant factors in Fig. 4 . A and B, relationship between prediction accuracy and exponent of allometric scaling for CL prediction using allometric scaling corrected by in vitro CL int (A) and V ss prediction using conventional allometric scaling (B). Solid and dotted lines represent the range of exponent of 0.7 to 1.1 and twofold error, respectively. C and D, relationship between the observed and predicted human values for CL (C) and V ss (D). E and F, relationship between the observed and predicted human values of the compounds with exponent ranged 0.7 to 1.1 for CL (E) and V ss (F). Solid and dotted lines indicate unity and twofold errors between predicted and observed values, respectively. pharmacokinetics. For prediction strategy, a preliminary index to speculate the predictability of plasma concentration profiles would help to consider the risk or variation range of the predicted data to justify the selection of a development compound or the design of firstin-human studies. With the allometric scaling of CL, the exponent is reported to be a key parameter to keep the trend of predictability in perspective, as demonstrated by the ROE method in which the MLP or BrW approach is selected based on the exponent in simple allometry (Mahmood and Balian, 1996) . We focused our attention on the relationship between the exponent and fold error of CL and V ss in allometric scaling. The relationship was noticeably described by a horseshoe curve for CL and V ss , and the compounds for which the exponent ranged from 0.7 to 1.1 showed better predictability compared with the compounds with an exponent ,0.7 or .1.1. With the hybrid method, usefulness of the exponent of CL and/or V ss as an index to predictability was investigated using 15 compounds. Compounds with both the exponents ranging from 0.7 to 1.1 yielded the highest level of prediction accuracy. Furthermore, the predictability of CL appeared to be guaranteed by the exponent from 0.7 to 1.1 for CL, and a similar relationship between the exponent and predictability would be noted for V ss . On the basis of these findings, the exponent according to the hybrid approach would become an effective index to preliminarily evaluate the predictability of the plasma concentration-time curves prior to clinical studies.
There are hardly any reports in the literature on the relationship between the exponent and the prediction accuracy in the allometric concept, and only a report by Huh et al. (2011) illustrated that accuracy was high with an exponent of 0.65 to 0.7 for small molecular drugs. However, please note that this result was obtained from single species scaling. Accordingly, our study is possibly the first challenge that highlights the utility of exponent to prospectively evaluate the predictability of human pharmacokinetics by the allometric concept.
In conclusion, we successfully developed a hybrid approach based on the Dedrick approach and the in vitro CL int in animal species and humans. The hybrid method yielded better predictability compared with the conventional Dedrick approach and the PBPK method. We also demonstrated that the exponent in the hybrid approach is an effective index to preliminarily analyze the accuracy of the predicted human pharmacokinetics prior to clinical studies. In fact, the plasma concentration-time curves were highly predictable for compounds with an exponent of 0.7 to 1.1 for both CL and V ss by the hybrid method. The new combination of the hybrid method and the index of exponent, which is a robust prediction tool, would allow us to predict the pharmacokinetic profiles in humans as well as to address the risk assessment.
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